• Tobias Franiel, Lutz Lüdemann, Birgit Rudolph, Hagen Rehbein, Andrea Staack, Matthias Taupitz, Daniel Prochnow, and Dirk Beyersdorff.
• Departments of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany. tobias.franiel@charite.de
• Invest Radiol. 2008 Jul 1; 43 (7): 481-7.

ObjectiveTo quantify independent pharmacokinetic parameters for differentiation of prostate pathology.Material And MethodsTwenty-seven patients with biopsy-proven prostate cancer (PSA: 1.4-16.1 ng/mL) underwent magnetic resonance imaging with a new dynamic contrast-enhanced, inversion-prepared dual-contrast gradient echo sequence (T1/T2*-weighted, 1.65 seconds temporal resolution) using a combined endorectal/body phased-array coil at 1.5 Tesla. Perfusion, blood volume, mean transit time, delay, and dispersion were calculated using a sequential 3-compartment model. Twenty-three patients underwent prostatectomy. For histologic correlation a pathologist mapped areas of normal prostate tissue, chronic prostatitis, and prostate cancer (total of 63 areas) on histologic sections corresponding to the magnetic resonance imaging planes.ResultsCompared with normal prostate tissue, low-grade cancer (Gleason score ConclusionThe pharmacokinetic parameters investigated, especially perfusion, allow statistically significant in situ differentiation of normal prostate tissue from cancer and chronic prostatitis and of high-grade cancer from chronic prostatitis.

25 keywords...

hide…